Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1 Trial to Investigate the Safety, Pharmacokinetic Profiles and the Efficacy of Tinostamustine, a First-in-Class Alkylating Histone Deacetylase Inhibition (HDACi) Fusion Molecule, in Relapsed/Refractory Hematologic Malignancies

Trial Profile

A Phase 1 Trial to Investigate the Safety, Pharmacokinetic Profiles and the Efficacy of Tinostamustine, a First-in-Class Alkylating Histone Deacetylase Inhibition (HDACi) Fusion Molecule, in Relapsed/Refractory Hematologic Malignancies

Status: Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 18 Jan 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Tinostamustine (Primary)
  • Indications Carcinoma; Cutaneous T-cell lymphoma; Diffuse large B cell lymphoma; Fallopian tube cancer; Haematological malignancies; Hodgkin's disease; Multiple myeloma; Mycosis fungoides; Non-Hodgkin's lymphoma; Ovarian cancer; Peripheral T-cell lymphoma; Peritoneal cancer; Sezary syndrome; Small cell lung cancer; Soft tissue sarcoma
  • Focus Adverse reactions; First in man; Therapeutic Use
  • Sponsors Mundipharma GmbH
  • Most Recent Events

    • 12 Dec 2023 Results (n=48) assessing safety and efficacy findings for tinostamustine in an expansion cohort of patients with CTCL in patients with advanced haematological malignancies presented at the 65th American Society of Hematology Annual Meeting and Exposition
    • 12 Dec 2023 Results (n=48) reporting safety and efficacy findings from cohort expansion portion of this trial in haematological malignancies patients presented at the 65th American Society of Hematology Annual Meeting and Exposition
    • 20 Sep 2023 Planned End Date changed from 1 Sep 2023 to 1 Dec 2023.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top